TORONTO, CANADA, September 21, 2023 - Today, Allergan Aesthetics, an AbbVie company, announced the Health Canada approval of SKINVIVE™ by JUVÉDERM®, an Hyaluronic Acid (HA) microdroplet injectable treatment delivering long-lasting*, deep† hydration for up to nine months and improvements in skin texture for up to six months following a single treatment1,6,‡,‡‡
SKINVIVE™ by JUVÉDERM® is indicated for treatment of the face (cheek, forehead) and neck, by filling of superficial cutaneous depressions such as fine lines and for additional improvement of hydration1.
SKINVIVE™ by JUVÉDERM® is a specialized, smooth, hydrating hyaluronic acid (HA) gel administered through intradermal microdroplet injections and that can be used on all Fitzpatrick Skin Types I-VI, addressing an important unmet need in the skin quality category.2 SKINVIVE™ delivers deep† hydration1, ‡ by leveraging the power of HA and boosting levels of AQP32,§ – a biological marker of hydration4 . The deep† hydration‡ with SKINVIVE™ helps patients achieve refreshed¶ glowing** and healthy-looking skin1,3, †† In clinical studies, 90.8% patient reported improved satisfaction 1 month after treatment3. Treatment is backed by a well-established safety profile with minimal downtime1,3 and can be flexibly used in combination with other aesthetic treatments5,8.
“SKINVIVE™ by JUVÉDERM® is an innovative HA gel product that reflects Allergan Aesthetics’ commitment to aesthetic medicine by delivering a premium, advanced, and clinically proven aesthetic treatment for patients and health care practitioners,” said Carolina Martin, General Manager, Allergan Aesthetics Canada. “This is the latest addition to our growing portfolio of products in the skin quality category and through our investment in R&D we’ll continue to bring innovations like this one to patients.”
Healthy-looking skin is a globally desired attribute6,7 and a recent global survey showed 94 per cent of people expressed a desire to improve their facial skin quality.6 Hydration is at the core of skin quality6 and SKINVIVE™ by JUVÉDERM® offers deep, long-lasting hydration from within, resulting in improvements in skin hydration and smoothness, and a lasting glow, supported by strong clinical data1,3,6**
“Improving skin quality requires an individualized, multi-layer treatment approach that goes beyond the skin’s surface,” said Dr. Shannon Humphrey, a Vancouver-based Dermatologist. “Hydration is a key factor that contributes to the overall condition of the skin, affecting surface texture, colour, ability to reflect light and physiological properties. Hyaluronic acid is one of the key molecules involved in skin moisture and hydration, and SKINVIVE™ by JUVÉDERM® works beneath the skin’s surface to increase skin hydration, improving skin quality. This is a foundational treatment for patients desiring hydration and glow.”
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.ca or follow us on Instagram at @allerganaestheticsCA
About Brilliant Distinctions
Consumers and new patients who receive aesthetic treatment from the Allergan Aesthetics portfolio of products can also enroll in Brilliant Distinctions, Allergan Aesthetics loyalty rewards program to unlock access to curated content, exclusive offers, and cash back from qualified purchases from the Allergan Aesthetics portfolio of products, subject to applicable program terms and conditions. For more information, visit https://www.brilliantdistinctions.ca/
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com
*Long lasting is up to 9 months following a single treatment.1
† Skin hydration was measured using the MoistureMeterD instrument with the XS 5 and S 15 probes (depth of effective measurement: 0.5 and 1.5 mm, respectively).1
‡ Instrument measures of skin hydration, smoothness, and skin deformation parameters were performed on the cheek, forehead, and neck of one side of the face on Day 0 and at 30 days after initial treatment (before touch up), Months 1, 4, 6, and 9 after the last treatment, and Month 1R. Skin hydration was measured using the MoistureMeterD instrument (n=131) and top-up treatment administered at Day 30 (n=31).1
‡‡ Based on a search of published clinical studies of injectable HA treatments in March 2023. A duration of 9 months of skin hydration was established with SKINVIVE™.6
§ Lasting up to 9 months as reported by 55.1% of patients. As reported by patients (127/131) in a composite satisfaction score, which includes how smooth their facial skin looked.3
¶ Lasting up to 9 months as reported by 63% of patients. As reported by patients (127/131) in a composite satisfaction score, which includes how radiant their facial skin looked.3
** Data derived from a prospective, non-randomized, interventional, open-label study where 11 healthy patients (men [n=2] and women [n=9]) received intradermal VYC-12L treatment on the volar forearm. Clinical probes assessed skin quality at baseline and Months 1 and 3 post-treatment. Punch biopsies were collected at Months 1 and 3 post-treatment to evaluate histologic and genomic changes.2
†† 9–24 months depending on the area treated and product used.10–12
1. Niforos F et al. Clin Cosmet Investig Dermatol. 2019;12:791–798.
2. Safa M et al. Clin Cosmet Investig Dermatol. 2022;15:411–426.
3. Ogilvie P et al. J Cosmet Dermatol. 2020;19(5):1065–1070.
4. Draelos Z. J Clin Aesthet Dermatol. 2012;5(7):53–56.
5. Zarbafian M et al., Safety of VYC-12 as a Combination Treatment for Skin Rejuvenation: A Retrospective Analysis of 1577 Treatments. Dermatol Surg. 2022 Mar 1;48(3):369-372.
6. Humphrey S, et al. Dermatol Surg 2021;47(7):974–81
7. Goldie K et al. Clin Cosmet Investig Dermatol. 2021;14:643–654.
8. Bertossi D et al., The skin rejuvenation associated treatment-Fraxel laser, Microbotox, and low G prime hyaluronic acid: preliminary results. Lasers Med Sci. 2019 Sep;34(7):1449-1455.
For media inquiries please contact: